

**RISANKIZUMAB solution for injection (Skyrizi® ▼)
for moderate to severe plaque psoriasis**

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of RISANKIZUMAB solution for injection (Skyrizi® ▼) for moderate to severe plaque psoriasis.

GREY

Risankizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.¹

This recommendation will be reviewed when the NICE TA is published. This is expected to be in August 2019.

In the meantime, clinicians should continue to follow local and national guidance on the treatment of plaque psoriasis:

- > Pan Mersey Area Prescribing Committee Policy Statement: [Psoriasis in adults, sequential use of biological agents](#) (last updated May 2019).
- > National Institute for Health and Care Excellence: [Psoriasis Pathway](#) (last updated 16 April 2019).

References

1. AbbVie Ltd. Summary of Product Characteristics. [Skyrizi 75 mg solution for injection in pre-filled syringe](#), 26 April 2019. Accessed online 16 May 2019.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.